Divis Laboratories Ltd

Q1 FY27, unaudited

Revenue: ₹3,080.00 Cr
Profit after tax: ₹902.00 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ crore	Q1 FY27	vs a year ago	6M FY26
Revenue from operations	3,080.00	+27.80%	2,831.00
Other income	64.00	−46.22%	155.00
Total income	3,144.00	+24.32%	2,986.00
Employee benefit expense	408.00	+20.00%	381.00
Finance costs	6.00	+100.00%	6.00
Depreciation & amortisation	133.00	+18.75%	120.00
Total expenses	1,964.00	+9.35%	2,023.00
Profit before tax	1,180.00	+60.98%	963.00
Tax expense	278.00	+47.87%	212.00
Profit after tax	902.00	+65.50%	751.00
Total comprehensive income	904.00	+64.96%	750.00

Earnings per share
Earnings per share, basic	₹33.95	₹28.31
Earnings per share, diluted	₹33.95	₹28.31

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

6M FY26 — from the company’s filing with NSE. Source

Earnings call

Q1 FY27

Divi's Laboratories reported consolidated total income of ₹3,144 crores for Q1 FY27 compared to ₹2,529 crores a year earlier, with profit after tax at ₹902 crores versus ₹545 crores in the same period last year. Management said standalone revenue grew 10% on a constant currency basis, with Custom Synthesis contributing 60% of revenue and Generics 40%. Management also discussed elevated solvent costs, a three-month rolling inventory strategy to secure supply, and progress on validation batches across peptide, generic and custom synthesis projects.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 30 published by the exchange

10 Aug 2026
Filing
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
10 Aug 2026
Filing
Shareholder Meeting / Postal Ballot-Outcome of AGM
06 Aug 2026
Transcript
Earnings Call Transcript
03 Aug 2026
Filing
Newspaper Publication
01 Aug 2026
Concall
Analyst / Investor Meet - Outcome
01 Aug 2026
Filing
Change in Management
01 Aug 2026
Board meeting
Board Meeting Outcome for Outcome Of Board Meeting Held On August 01, 2026.
31 Jul 2026
Filing
Change in Management
24 Jul 2026
Concall
Analyst / Investor Meet - Intimation
20 Jul 2026
Board meeting
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2026.
17 Jul 2026
Filing
Newspaper Publication
15 Jul 2026
Filing
Notice Of 36Th Annual General Meeting To Be Held On August 10, 2026

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 10 Aug 2026.